Jynarque 90MG-30MG
Ended Awarded
- Contract number
- 36C24524N0225
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $12,196
Award facts
- Contract value 100% obligated
- $12,195.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
Otsuka America Pharmaceutical Inc. received a $12,195.72 firm fixed price delivery order from Veterans Integrated Service Network 5 (VISN 5), a civilian component of the Department of Veterans Affairs, for Jynarque 90mg-30mg pharmaceutical products. The award, issued on December 12, 2023, with an ultimate completion date of December 15, 2023, represents a direct procurement under the company's broader Blanket Purchase Agreement with the VA's National Acquisition Center valued at approximately $83.3 million. This delivery order does not utilize a set-aside designation and falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), with performance to occur in Pittsburgh, Pennsylvania.
Jynarque (tolvaptan) is a specialized pharmaceutical treatment for autosomal dominant polycystic kidney disease and hyponatremia primarily supplied to VA medical facilities supporting veteran healthcare. Otsuka America Pharmaceutical Inc., headquartered in Rockville, Maryland, maintains a substantial federal presence as a large pharmaceutical manufacturer with multiple indefinite delivery vehicles across VA Integrated Service Networks, including a $396 million Federal Supply Schedule contract. This delivery order exemplifies the streamlined procurement process that enables VA medical centers to efficiently obtain critical specialty pharmaceutical treatments for veterans across multiple regional networks.
Quick answers
Who was awarded contract 36C24524N0225?
36C24524N0225 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on December 12, 2023.
How much is contract 36C24524N0225 worth?
The government has obligated $12,196 on 36C24524N0225.
Is contract 36C24524N0225 an order under another contract?
Yes. 36C24524N0225 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24524N0225 competed?
The extent of competition for 36C24524N0225 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award